Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma

• Kamel Laribi,
• Alix Baugier de Materre,
• Yamina Touileb,
• Charles Boursot,
• Jeremy Sandrini,
• Doriane Cavalieri,
• Cédric Pastoret,
• Laurence de Leval,
• Olivier Tournilhac

Affiliations

Kamel Laribi

1 Department of Haematology, Centre Hospitalier Le Mans, France

Alix Baugier de Materre

2 Geriatric Department, Assistance Publique-Hôpitaux de Paris, Hôpital Broca, Paris, France

Yamina Touileb

1 Department of Haematology, Centre Hospitalier Le Mans, France

Charles Boursot

3 Department of Nuclear Medicine, Centre Hospitalier Le Mans, France

Jeremy Sandrini

4 Department of Anatomopathology, Centre Hospitalier Le Mans, France

Doriane Cavalieri

5 Haematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, France

Cédric Pastoret

7 Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, France

Laurence de Leval

8 Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and Lausanne University, Switzerland

Olivier Tournilhac

5 Haematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, France